ME3241 / Meiji Seika - LARVOL DELTA

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Meiji Pharma USA Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human

Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI (Businesswire) - "The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics....The initiation of the Phase I clinical trial of an autoimmune disease therapy by a PD-1 agonist antibody is highly significant..."

First-in-human • Trial status • Immunology

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=104 | Not yet recruiting | Sponsor: Meiji Pharma USA Inc.

First-in-human • New P1 trial